NextCure, a clinical-stage biotech developing cancer immunotherapies, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Beltsville, MD-based company was founded in 2015 and plans to list on the Nasdaq under the symbol NXTC. NextCure filed confidentially on January 30, 2019. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
